Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus

Trends in Endocrinology and Metabolism

Volumn 27, Issue 1, 2016, Pages 24-34

  Tang, Wei Jen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alzheimer's disease; Insulin degrading enzyme; Small molecule inhibitors; Type 2 diabetes mellitus

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; INSULIN; INSULINASE;

ALZHEIMER DISEASE; BIOCHEMICAL ANALYSIS; ENZYME ACTIVITY; ENZYME STRUCTURE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; REVIEW; STRUCTURE ANALYSIS; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; INSULIN; INSULYSIN; ISLET AMYLOID POLYPEPTIDE;

EID: 84952639447     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.11.003     Document Type: Review

References (83)

1. Duckworth W.C., et al. Insulin degradation: progress and potential. Endocr. Rev. 1998, 19:608-624.
2. Kurochkin I. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 2001, 26:421-425.
3. Malito E., et al. Amyloid β-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 2008, 65:2574-2585.
4. Qiu W., Folstein M. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimers disease: review and hypothesis. Neurobiol. Aging 2006, 27:190-198.
5. Maianti J.P., et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature 2014, 511:94-98.
6. Mirsky I.A., Broh-Kahn R.H. The inactivation of insulin by tissue extracts; the distribution and properties of insulin inactivating extracts. Arch. Biochem. 1949, 20:1-9.
7. Manolopoulou M., et al. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J. Biol. Chem. 2009, 284:14177-14188.
8. Tundo G.R., et al. Insulin-degrading enzyme (IDE): a novel heat shock-like protein J. Biol. Chem. 2013, 288:2281-2289.
9. Wei X., et al. Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice. PLoS ONE 2014, 9:e95399.
10. Ralat L.A., et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J. Biol. Chem. 2011, 286:4670-4679.
11. Song E.S., et al. A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties. PLoS ONE 2010, 5:e9719.
12. McCord L.A., et al. Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:13827-13832.
13. Song E.S., et al. Mixed dimers of insulin-degrading enzyme reveal a cis activation mechanism. J. Biol. Chem. 2011, 286:13852-13858.
14. Song E.S., et al. ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety. J. Biol. Chem. 2004, 279:54216-54220.
15. Shen Y., et al. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 2006, 443:870-874.
16. Im H., et al. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J. Biol. Chem. 2007, 282:25453-25463.
17. Noinaj N., et al. Anion activation site of insulin-degrading enzyme. J. Biol. Chem. 2012, 287:48-57.
18. Chou Y-H.Y., et al. Structural changes in intermediate filament networks alter the activity of insulin-degrading enzyme. FASEB J. 2009, 23:3734-3742.
19. Sbardella D., et al. Proteasome activity is affected by fluctuations in insulin-degrading enzyme distribution. PLoS ONE 2015, 10:e0132455.
20. Bulloj A., et al. Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-β degrading protease. J. Alzheimers Dis. 2010, 19:79-95.
21. Tamboli I.Y., et al. Statins promote the degradation of extracellular amyloid β-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (ide) secretion. J. Biol. Chem. 2010, 285:37405-37414.
22. Vingtdeux V., et al. CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain. J. Cell Sci. 2015, 128:2330-2338.
23. Glebov K., et al. Functional relevance of a novel SlyX motif in non-conventional secretion of insulin-degrading enzyme. J. Biol. Chem. 2011, 286:22711-22715.
24. Prentki M. Islet β cell failure in type 2 diabetes. J. Clin. Invest. 2006, 116:1802-1812.
25. Farris W., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4162-4167.
26. Farris W., et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am. J. Pathol. 2004, 164:1425-1434.
27. Michael M.D., et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 2000, 6:87-97.
28. Miller B.C., et al. Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6221-6226.
29. Deprez-poulain R., et al. Catalytic site inhibition of insulin degrading enzyme by a small molecule induces glucose intolerance in mice. Nat. Commun. 2015, 6:8250.
30. Hayes M.R., et al. Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu. Rev. Nutr. 2014, 34:237-260.
31. Jiang G., Zhang B.B. Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E671-E678.
32. Jones B.J., et al. Minireview: Glucagon in stress and energy homeostasis. Endocrinology 2012, 153:1049-1054.
33. Abdul-Hay S.O., et al. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PLoS ONE 2011, 6:e20818.
34. Gilbert B.J. The role of amyloid β in the pathogenesis of Alzheimer's disease. J. Clin. Pathol. 2013, 66:362-366.
35. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
36. Leissring M.A., et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
37. Ye J. Mechanisms of insulin resistance in obesity. Front. Med. 2013, 7:14-24.
38. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 2001, 32:177-180.
39. Leissring M.A. The AβCs of Aβ-cleaving proteases. J. Biol. Chem. 2008, 283:29645-29649.
40. King J.V., et al. Molecular basis of substrate recognition and degradation by human presequence protease. Structure 2014, 22:996-1007.
41. Ghosh S., et al. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am. J. Hum. Genet. 2000, 67:1174-1185.
42. Kim M., et al. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J. Biol. Chem. 2007, 282:7825-7832.
43. Sladek R., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
44. Zeggini E., et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316:1336-1341.
45. Flannick J., et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat. Genet. 2014, 46:357-363.
46. Bertram L., et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000, 290:2302-2303.
47. Bertram L., et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
48. Prince J.A., et al. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum. Mutat. 2003, 22:363-371.
49. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
50. Carrasquillo M.M., et al. Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Aβ, and Alzheimer's disease. PLoS ONE 2010, 5:e8764.
51. Maurer M., von Stebut E. Macrophage inflammatory protein-1. Int. J. Biochem. Cell B 2004, 36:1882-1886.
52. Ren M., et al. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. 2010, 29:3952-3966.
53. Parmentier N., et al. Production of an antigenic peptide by insulin-degrading enzyme. Nat. Immunol. 2010, 11:449-454.
54. Kim Y-G., et al. Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:8523-8527.
55. Russell F.A., et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev. 2014, 94:1099-1142.
56. Llovera R.E., et al. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid β peptide implications for Alzheimer disease. J. Biol. Chem. 2008, 283:17039-17048.
57. Steneberg P., et al. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of α-synuclein levels in β-cells. Diabetes 2013, 62:2004-2014.
58. Sharma S.K., et al. Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner. Sci. Rep. 2015, 5:12531.
59. Mukherjee A., et al. Type 2 diabetes as a protein misfolding disease. Trends Mol. Med. 2015, 21:439-449.
60. Powers E.T., et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 2009, 78:959-991.
61. Guo Q., et al. Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme. J. Mol. Biol. 2010, 395:430-443.
62. Malito E., et al. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme. Biochemistry 2008, 47:12822-12834.
63. Noinaj N., et al. Identification of the allosteric regulatory site of insulysin. PLoS ONE 2011, 6:e20864.
64. Mirsky I.A., Perisutti G. Effect of insulinase-inhibitor on hypoglycemic action of insulin. Science 1955, 122:559-560.
65. Bennett R.G., et al. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 2003, 52:2315-2320.
66. Leissring M.A.M., et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS ONE 2010, 5:e10504.
67. Charton J., et al. Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis. Eur. J. Med. Chem. 2014, 79:184-193.
68. Charton J., et al. Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme. Eur. J. Biochem. 2015, 90:547-567.
69. Durham T.B., et al. Dual exosite-binding inhibitors of insulin-degrading enzyme challenge its role as the primary mediator of insulin clearance in vivo. J. Biol. Chem. 2015, 290:20044-20059.
70. Costes S., Butler P.C. Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?. Cell Metab. 2014, 20:201-203.
71. DeMattos R.B., et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8850-8855.
72. Zhang Y., Lee D.H. Sink hypothesis and therapeutic strategies for attenuating Aβ levels. Neuroscientist 2011, 17:163-173.
73. Liu-Seifert H., et al. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimers Dement. Transl. Res. Clin. Interv. 2015, 1:111-121.
74. Caravaggio J.W., et al. Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice. Cardiovasc. Pathol. 2013, 22:458-464.
75. Haataja L., et al. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 2008, 29:303-316.
76. Hull R.L., et al. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:3629-3643.
77. Abdul-Hay S.O., et al. Selective targeting of extracellular insulin-degrading enzyme by quasi-irreversible thiol-modifying inhibitors. ACS Chem. Biol. 2015, Published online October 16, 2015. 10.1021/acschembio.5b00595.
78. Bannister T.D., et al. ML345, a Small-Molecule Inhibitor of the Insulin-Degrading Enzyme (IDE) 2010, Probe Reports from the NIH Molecular Libraries Program.
79. Ralat L.A., et al. Protective role of Cys-178 against the inactivation and oligomerization of human insulin-degrading enzyme by oxidation and nitrosylation. J. Biol. Chem. 2009, 284:34005-34018.
80. Shinall H., et al. Susceptibility of amyloid β peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 2005, 44:15345-15350.
81. Song E.S., et al. An extended polyanion activation surface in insulin degrading enzyme. PLoS ONE 2015, 10:e0133114.
82. Cabrol C., et al. Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS ONE 2009, 4:e5274.
83. Son S.M., et al. Statins induce insulin-degrading enzyme secretion from astrocytes via an autophagy-based unconventional secretory pathway. Mol. Neurodegener. 2015, 10:56.